Sign In
Buy PFE
$26.04
+0.350 (+1.36%)
At Close: Jun 05, 2026
New omicron variant worries experts as it spreads in India, and Moderna says new booster offers better protection against BA.4 and BA.5
05:58pm, Monday, 11'th Jul 2022 MarketWatch
A new, highly infectious subvariant of omicron is raising concerns among scientists and health experts as it spreads in India and other countries, including the U.S.
How Its New Vaccine Could Propel GSK's Growth
11:00am, Monday, 11'th Jul 2022 The Motley Fool
GSK leads the race to deliver a vaccine for an untreated infectious disease.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
10:20am, Monday, 11'th Jul 2022 Zacks Investment Research
Sector ETF report for IHE
Nicholas Ward's Dividend Growth Portfolio: June 2022 Update
05:46pm, Sunday, 10'th Jul 2022 Seeking Alpha
My passive income was up by 23.32% during June. I made 13 trades during the month; 11 purchases and 2 sales. Click here for my portfolio update for June 2022.
Beat The Bear With 3 Tools: Dividends, Dividends And Dividends
12:28pm, Sunday, 10'th Jul 2022 Investing.com
Why This Promising Drug Will Be Pfizer's Next Blockbuster
02:45pm, Saturday, 09'th Jul 2022 The Motley Fool
Pfizer shared encouraging clinical trial results for a drug candidate focused on treating a form of inflammatory bowel disease.
3 No-Brainer Stocks to Buy in July
10:08am, Saturday, 09'th Jul 2022 The Motley Fool
These stocks appear to be clear winners.
Pharma Stock Roundup: AZN's Small Cancer Firm Buyout, FDA Updates for PFE, RHHBY
03:34pm, Friday, 08'th Jul 2022 Zacks Investment Research
FDA grants priority review to Roche's (RHHBY) BLA for Lunsumio. AstraZeneca (AZN) announces a small acquisition. Pfizer (PFE) files NDA for Paxlovid.
Biohaven (BHVN) Begins Phase III Study on SMA Candidate
03:09pm, Friday, 08'th Jul 2022 Zacks Investment Research
Biohaven (BHVN) commenced enrollment in a phase III study to evaluate its muscle-targeted recombinant protein candidate, taldefgrobep alfa, in patients with SMA.
The U.S. bets billions of dollars on better COVID-19 boosters as it prepares for a spike in COVID-19 cases next winter
07:14pm, Friday, 01'st Jul 2022 MarketWatch
The U.S. is gearing up for another wave of COVID-19 infections in the fall and winter following a flurry of activity this week.
FDA and drug makers deepen their commitment to clinical-trial diversity. Will it work?
07:00pm, Friday, 01'st Jul 2022 MarketWatch
After years of ‘lackluster’ efforts, regulators and companies are finally aligned in their goal to make clinical trials more representative of U.S. population.
Pfizer (PFE) Seeks FDA Nod for Its Oral Antiviral COVID Pill
02:56pm, Friday, 01'st Jul 2022 Zacks Investment Research
Pfizer (PFE) submits NDA to the FDA seeking approval for using its oral antiviral COVID pill in vaccinated and unvaccinated patients at a high risk of developing severe COVID-19 complications.
FDA Recommends Adding New Omicron Subvariants to COVID Boosters
01:45pm, Friday, 01'st Jul 2022 Zacks Investment Research
In anticipation of a new surge of COVID-19 infections later this year, the FDA recommends that COVID-19 vaccine manufacturers develop bivalent booster vaccines that contain the BA.4/BA.5 Omicron subva
Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
01:00pm, Friday, 01'st Jul 2022 Zacks Investment Research
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Why This Company Could See Long-Lasting Tailwinds Despite the Bear Market
11:47am, Friday, 01'st Jul 2022 The Motley Fool
An industry-leading company looks past COVID-19 to future growth.
